NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vico Therapeutics

Vico Therapeutics

Private
LeidenHealthcare & Life Scienceshttps://vicotx.com/

Last Round

Series B

Extension

Jun 24, 2024

Total Funding Raised

$114.1M

Company Overview

Vico Therapeutics is a biotechnology company that develops RNA-modulating antisense oligonucleotide (ASO) therapies aimed at treating patients with severe, rare neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

antisense oligonucleotideASO therapyRNA modulationgenetic medicinesgene silencingrare neurological disordersHuntington's diseasespinocerebellar ataxiaSCApolyglutamine diseasesclinical-stage biotechCAG repeat suppressionorphan drugsOrphan Drug DesignationRett SyndromeRNA editingASO discovery platformintrathecal delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vico Therapeutics Comparables

Compare Vico Therapeutics with similar companies based on industry and business-model similarity.

Vico Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Wave Life Sciences
81%
ProQR Therapeutics
79%
Stoke Therapeutics, Inc.
76%

Vico Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJun 24, 2024
Series BJan 5, 2024
Series AJul 29, 2020

Vico Therapeutics Investors

Notable investors and investment history

Vico Therapeutics investors
InvestorRounds
Ackermans & van HaarenSeries B Extension, Series B
EQT Life SciencesSeries B Extension, Series A, Series B
Idinvest PartnersSeries A
Seroba Life SciencesSeries B Extension
Pontifax CreditSeries A
Droia VenturesSeries B Extension, Series A, Series B
Pureos BioventuresSeries A, Series B, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Product candidate VO659 is undergoing a first-in-human study for rare neurological disorders.

  • Jun 22, 2025

    Job posting indicates preparation for IPO as part of growth strategy.

Vico Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vico Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vico Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLeiden
Employee Range49
Year Founded2019
Last FundingJun 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.